We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Monthly Production Capacity: large capacity
Contract Manufacturing: Workable
Packaging Information: According to customs' requirements
Delivery Lead Time: USP, BP, EP etc
Sample Provided: no
Payment Terms: depends, normally about 2 months
Product : Salmeterol Fluticasone Aerosol Metered
Specification : (25mcg+50mcg)/dose×120 doses;(25mcg +125mcg)/dose×120 doses;(25mcg+250mcg)/dose×120 doses
Standard : BP, USP
Packing : one bottle/box
Description :
Fluticasone Propionate And Salmeterol Xinafoate Aerosol Metered is an inhalation aerosol. Each actuation delivers a combination of fluticasone propionate and salmeterol (250/25 mcg) from the actuator.
Fluticasone is a steroid that prevents the release of substances in the body that cause inflammation. Salmeterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing.
Indication :
Prescription Medicine for the treatment of reversible obstructive airway disease (ROAD) including asthma, and for the treatment of chronic obstructive pulmonary disease (COPD).
In people with COPD, fluticasone and salmeterol is for long-term treatment. In people with asthma, this medicine is for short-term treatment until symptoms are well controlled with with other medicines.
Three years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
